Target intelligence / Profile preview

Von Willebrand factor C domain containing 2 (VWC2)

Target
VWC2
Molecular classification
Protein coding gene, Secreted protein, Bone morphogenic protein antagonist, Extracellular matrix-related protein
01

Overview

Von Willebrand factor C domain containing 2 (VWC2) is a secreted protein primarily known as a bone morphogenetic protein antagonist, regulating BMP signaling in the extracellular space. It is involved in neural development, cell adhesion, and may play a role in bone formation and differentiation. VWC2 is part of a family of proteins containing the von Willebrand factor type C domain, which provides versatile binding characteristics for protein-protein interactions in development and pattern formation. Its function as a BMP antagonist positions it as a regulatory molecule rather than a classical receptor or enzyme, impacting growth factor signaling cascades relevant to skeletal and neural development.

Other names
VWC2BRORINVon Willebrand factor type C domain-containing protein 2HGNC:30200UniProtKB: Q2TAL6
02

Mechanism of action

BMP antagonist: inhibits signaling of bone morphogenetic proteins via competitive binding, particularly BMP-2 and BMP-6, affecting receptor interaction and downstream signaling. Modulation of extracellular signaling complexes affecting neural and bone development pathways.

03

Biological functions

Negative regulation of BMP signaling pathwayNeural development and functionCell adhesionPotential role in bone differentiation and matrix mineralizationRegulator of neuron differentiation (predicted)
04

Disease associations

Musculoskeletal developmental syndromes: Tarsal-Carpal Coalition Syndrome, Sclerosteosis 1 (associations found via VWC2L paralog)Potential implications in diseases involving BMP signaling, neural development, and extracellular matrix homeostasis (based on pathway roles)
05

Safety considerations

No established safety concerns for direct targeting of VWC2. Disruption of BMP signaling can lead to adverse effects on bone development and neural function, suggesting caution in therapeutic modulation
06

Biomarkers

No established clinical biomarkers found for VWC2 itself; may be investigational in contexts involving BMP signaling dysregulation or diseases like Sclerosteosis

Beyond the preview

Go deeper on Von Willebrand factor C domain containing 2 (VWC2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Von Willebrand factor C domain containing 2 (VWC2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call